Why A Structured System Matters 
How The System Helps You Succeed 
How Implementation Works 
What’s Included in the System 
Real Practice Outcomes 
Scaling a Profitable Practice 
Patient Demand 
Patient Education 
Staff Education 
Marketing 
Regenerative Medicine Platform
Franchise & PE Support 
Wharton’s Jelly
Exosomes
Anti-Aging
Aesthetic Treatments
Neurological
Autoimmune
Wound Care
Orthopedic Conditions
Clinical Trials
Articles
Research Institutes
TB-500 is a synthetic peptide fragment of Thymosin Beta-4 (TB4), a naturally occurring 43–amino acid protein found in nearly all human and animal cells. TB4 plays a critical role in cell migration, angiogenesis, and tissue repair. TB-500 is designed as a shorter, more stable sequence of TB4 that retains its regenerative and wound-healing properties. It is studied in research for its potential to accelerate healing, reduce inflammation, and support recovery. TB-500 remains experimental and is not FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Studied for enhancing wound healing and recovery from soft tissue injuries.
- Explored in cardiovascular research for promoting angiogenesis and repair after ischemic injury.
- Investigated in ophthalmic studies for corneal healing and eye injury repair.
- Examined in musculoskeletal research for tendon, ligament, and joint recovery.
Proposed Uses (Research Areas)
- Wound healing and tissue repair models.
- Cardiac and vascular research.
- Musculoskeletal and sports injury studies.
- Ophthalmology and corneal healing research.
How It Is Dosed in Research Settings
- Injectable (Subcutaneous or Intramuscular): Research dosing commonly ranges from 2–5 mg, administered 1–2 times weekly.
- Cycle length: Typically studied in 4–6 week cycles, sometimes followed by maintenance doses every 1–2 weeks depending on research endpoints.
- Handling: Supplied as lyophilized powder; reconstituted with bacteriostatic water, stored refrigerated, and protected from light.
Important Considerations
- Regulatory status: TB-500 is not FDA-approved; all applications remain experimental.
- Evidence base: Preclinical and animal studies show enhanced healing and angiogenesis; controlled human research is very limited.
- Safety: Reported as generally well tolerated in research, but long-term human safety data is lacking. Potential concerns include undesired angiogenesis or fibrosis in non-target tissues.
Disclaimer
This material is provided for educational purposes only and summarizes published research on TB-500.
It is not medical advice. TB-500 is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.